Gilead Sciences Drops as Sales of Top-Selling Drugs Fall Short
- Antiviral treatments for hepatitis C, HIV miss estimates in Q1
- CEO Milligan says company not counting on tax reform
This article is for subscribers only.
Gilead Sciences Inc. fell after first-quarter sales of some of its best-selling antiviral treatments for hepatitis C and HIV failed to meet analysts’ expectations.
Truvada, a treatment for HIV, was the biggest disappointment, while Epclusa and Sovaldi for viral liver disease also fell short of analysts’ projections. Gilead’s stock dropped as much as 3.4 percent Wednesday, the most in almost three months.